Option Update; Myriad Genetics volatility Elevated into disappointing Alzheimer's data


Myriad Genetics (NASDAQ:MYGN) is recently down $5.48 to $42.25 in pre-open trading. MYGN's Flurizan, a treatment for Alzheimer's diseases, had negative Phase 3 results. RBC Capital has a 12-month forward target of $37 on MYGN. MYGN July option implied volatility of 102 was above its 26-week average of 71 according to Track Data, suggesting larger July price movement.


Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Symbol Lookup
IndexesChangePrice
DJIA+80.4512,881.68
NASDAQ+26.732,930.61
S&P 500+9.771,352.41

Last updated: February 13, 2012: 02:48 PM

Hot Stocks

General Electric

19.055+0.18(+0.95)

Alcoa

10.33+0.04(+0.39)

Apple Inc

501.14+7.72(+1.56)

Google Inc 'A'

613.17+7.26(+1.20)

Bank of America

8.295+0.225(+2.79)

Wal-Mart Stores

61.89-0.01(-0.02)

Exxon Mobil Corp

84.53+0.73(+0.87)

Ford

12.60+0.16(+1.29)

Citigroup

33.33+0.405(+1.23)

IBM

192.98+0.56(+0.29)

Yahoo

16.140.00(0.00)

Starbucks

49.20+0.38(+0.78)

Microsoft

30.705+0.21(+0.69)

Home Depot

46.095+0.765(+1.69)

DailyFinance Headlines

Benzinga Headlines

TheFlyOnTheWall.com Headlines

BioHealth Investor Headlines

WalletPop Headlines

DailyFinance BlackBerry App

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

BioHealth Investor Headlines

Page Loaded in 1329162522629 ms.